{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:10:11Z","timestamp":1793239811746,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01113"],"award-info":[{"award-number":["PI19\/01113"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP20\/00188"],"award-info":[{"award-number":["CP20\/00188"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["IDEAS19122MART"],"award-info":[{"award-number":["IDEAS19122MART"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PRDCR19007BREA_001"],"award-info":[{"award-number":["PRDCR19007BREA_001"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES207MART"],"award-info":[{"award-number":["INVES207MART"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED481A-2020\/214"],"award-info":[{"award-number":["ED481A-2020\/214"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN606B-2024\/014"],"award-info":[{"award-number":["IN606B-2024\/014"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN606A-2024\/017"],"award-info":[{"award-number":["IN606A-2024\/017"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06323-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:40:10Z","timestamp":1743842410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors"],"prefix":"10.1186","volume":"23","author":[{"given":"Jenifer","family":"Brea-Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gallardo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oitab\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao M.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pino-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Juaneda-Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Garc\u00eda-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab","family":"Abdulkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Muinelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Paramio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"6323_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade. JAMA Oncol. 2019;5:1195\u2013204.","journal-title":"JAMA Oncol"},{"key":"6323_CR2","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302\u201311.","journal-title":"J Thorac Oncol"},{"key":"6323_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","volume":"15","author":"S Lantuejoul","year":"2020","unstructured":"Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J Thorac Oncol. 2020;15:499\u2013519.","journal-title":"J Thorac Oncol"},{"key":"6323_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York NY). 2018. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science (New York NY)"},{"key":"6323_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136.","journal-title":"Nat Genet"},{"key":"6323_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner R, Longshore JW, L\u00f3pez-R\u00edos F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4: e000442.","journal-title":"ESMO Open"},{"key":"6323_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44\u201356.","journal-title":"Ann Oncol"},{"key":"6323_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13035-2","volume":"10","author":"Y Kong","year":"2019","unstructured":"Kong Y, Rose CM, Cass AA, Williams AG, Darwish M, Lianoglou S, et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nat Commun. 2019;10:1\u201314.","journal-title":"Nat Commun"},{"key":"6323_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41588-019-0562-0","volume":"52","author":"B Rodriguez-Martin","year":"2020","unstructured":"Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J, et al. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52:306\u201319.","journal-title":"Nat Genet"},{"key":"6323_CR10","doi-asserted-by":"publisher","first-page":"1251343","DOI":"10.1126\/science.1251343","volume":"345","author":"JMC Tubio","year":"2014","unstructured":"Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, et al. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014;345:1251343.","journal-title":"Science"},{"key":"6323_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","volume":"55","author":"NM Shah","year":"2023","unstructured":"Shah NM, Jang HJ, Liang Y, Maeng JH, Tzeng S-C, Wu A, et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat Genet. 2023;55:631\u20139.","journal-title":"Nat Genet"},{"key":"6323_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer\u2014mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20:604\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"6323_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-024-45361-5","volume":"15","author":"J Han","year":"2024","unstructured":"Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, et al. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun. 2024;15:1199.","journal-title":"Nat Commun"},{"key":"6323_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"6323_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384: e076743.","journal-title":"BMJ"},{"key":"6323_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, K\u00fcbler H, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36:43\u201353.","journal-title":"Urol Oncol"},{"key":"6323_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. Special series: thoracic oncology: current and future therapy review articles. J Clin Oncol. 2022;40:586\u201397.","journal-title":"J Clin Oncol"},{"key":"6323_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34:358\u201376.","journal-title":"Ann Oncol"},{"key":"6323_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"6323_CR20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25:1706\u201314.","journal-title":"Nat Med"},{"key":"6323_CR21","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/. Accessed 15 May 2024."},{"key":"6323_CR22","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv: Genomics. 2013."},{"key":"6323_CR23","first-page":"1754","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (Oxford, England). 2009;25:1754\u201360.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"6323_CR24","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10:giab008.","journal-title":"GigaScience."},{"key":"6323_CR25","unstructured":"Broad Institute. Picard Tools. http:\/\/broadinstitute.github.io\/picard\/."},{"key":"6323_CR26","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303.","journal-title":"Genome Res"},{"key":"6323_CR27","unstructured":"GATK Broad Institute, Caetano-Anolles D. Somatic short variant discovery (SNVs + Indels) https:\/\/gatk.broadinstitute.org\/hc\/en-us\/articles\/360035894731-Somatic-short-variant-discovery-SNVs-Indels."},{"key":"6323_CR28","doi-asserted-by":"publisher","unstructured":"Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling somatic SNVs and Indels with Mutect2. bioRxiv; 2019. p. 861054. https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/861054v1.","DOI":"10.1101\/861054v1"},{"key":"6323_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"6323_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073\u201381.","journal-title":"Nat Protoc"},{"key":"6323_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/0471142905.hg0720s76","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013. https:\/\/doi.org\/10.1002\/0471142905.hg0720s76.","journal-title":"Curr Protoc Hum Genet"},{"key":"6323_CR32","doi-asserted-by":"publisher","unstructured":"Kandoth C. mskcc\/vcf2maf: vcf2maf v1.6.19. 2020. https:\/\/doi.org\/10.5281\/zenodo.593251.","DOI":"10.5281\/zenodo.593251"},{"key":"6323_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"6323_CR34","doi-asserted-by":"publisher","first-page":"D936","DOI":"10.1093\/nar\/gks1213","volume":"41","author":"I Lappalainen","year":"2013","unstructured":"Lappalainen I, Lopez J, Skipper L, Hefferon T, Spalding JD, Garner J, et al. dbVar and DGVa: public archives for genomic structural variation. Nucleic Acids Res. 2013;41:D936\u201341.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR35","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.1038\/s41598-019-45839-z","volume":"9","author":"HM Amemiya","year":"2019","unstructured":"Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: identification of problematic regions of the genome. Sci Rep. 2019;9:9354.","journal-title":"Sci Rep"},{"key":"6323_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1186\/s12864-018-5330-5","volume":"19","author":"R Kumar","year":"2019","unstructured":"Kumar R, Nagpal G, Kumar V, Usmani SS, Agrawal P, Raghava GPS. HumCFS: a database of fragile sites in human chromosomes. BMC Genomics. 2019;19:985.","journal-title":"BMC Genomics"},{"key":"6323_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.25","volume":"3","author":"JM Zook","year":"2016","unstructured":"Zook JM, Catoe D, McDaniel J, Vang L, Spies N, Sidow A, et al. Extensive sequencing of seven human genomes to characterize benchmark reference materials. Sci Data. 2016;3: 160025.","journal-title":"Sci Data"},{"key":"6323_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171:1029-1041.e21.","journal-title":"Cell"},{"key":"6323_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature"},{"key":"6323_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575:210\u20136.","journal-title":"Nature"},{"key":"6323_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC20 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:41.","journal-title":"Genome Biol"},{"key":"6323_CR42","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90-97.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Curr Protoc. 2021;1: e90.","journal-title":"Curr Protoc"},{"key":"6323_CR44","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"6323_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"6323_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2019.00445","volume":"10","author":"R Huang","year":"2019","unstructured":"Huang R, Grishagin I, Wang Y, Zhao T, Greene J, Obenauer JC, et al. The NCATS BioPlanet\u2014an integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics. Front Pharmacol. 2019;10:445.","journal-title":"Front Pharmacol"},{"key":"6323_CR47","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gky962","volume":"47","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47:D590\u20135.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR48","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587\u201392.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060184","volume":"6","author":"AR Pico","year":"2008","unstructured":"Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR, Evelo C. WikiPathways: pathway editing for the people. PLoS Biol. 2008;6: e184.","journal-title":"PLoS Biol"},{"key":"6323_CR50","doi-asserted-by":"publisher","first-page":"D679","DOI":"10.1093\/nar\/gkad960","volume":"52","author":"A Agrawal","year":"2024","unstructured":"Agrawal A, Balc\u0131 H, Hanspers K, Coort SL, Martens M, Slenter DN, et al. WikiPathways 2024: next generation pathway database. Nucleic Acids Res. 2024;52:D679\u201389.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"6323_CR52","doi-asserted-by":"publisher","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","volume":"224","author":"SA Aleksander","year":"2023","unstructured":"The Gene Ontology Consortium, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224:iyad031.","journal-title":"Genetics"},{"key":"6323_CR53","doi-asserted-by":"crossref","first-page":"D87","DOI":"10.1093\/nar\/gkaa516","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48:D87-92.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR54","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","volume":"55","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2023","unstructured":"Mart\u00ednez-Jim\u00e9nez F, Priestley P, Shale C, Baber J, Rozemuller E, Cuppen E. Genetic immune escape landscape in primary and metastatic cancer. Nat Genet. 2023;55:820\u201331.","journal-title":"Nat Genet"},{"key":"6323_CR55","doi-asserted-by":"publisher","first-page":"D1053","DOI":"10.1093\/nar\/gkac1011","volume":"51","author":"DJ Barker","year":"2023","unstructured":"Barker DJ, Maccari G, Georgiou X, Cooper MA, Flicek P, Robinson J, et al. The IPD-IMGT\/HLA Database. Nucleic Acids Res. 2023;51:D1053\u201360.","journal-title":"Nucleic Acids Res"},{"key":"6323_CR56","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan 40: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360\u20138.","journal-title":"J Immunol"},{"key":"6323_CR57","doi-asserted-by":"publisher","unstructured":"Brea-Iglesias J, Oitaben A, Zumalave S, Rodriguez-Martin B, Gallardo-Gomez M, Santamarina M, et al. RetroTest unravels LINE-1 retrotransposition in head and neck squamous cell carcinoma. medRxiv; 2024. p. 2024.07.24.24310921. https:\/\/doi.org\/10.1101\/2024.07.24.24310921v2","DOI":"10.1101\/2024.07.24.24310921v2"},{"key":"6323_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2023;389:504\u201313.","journal-title":"N Engl J Med"},{"key":"6323_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jtho.2022.11.030","volume":"18","author":"SM Ernst","year":"2023","unstructured":"Ernst SM, Mankor JM, van Riet J, von der Th\u00fcsen JH, Dubbink HJ, Aerts JGJV, et al. Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC. J Thorac Oncol. 2023;18:487\u201398.","journal-title":"J Thorac Oncol"},{"key":"6323_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023;55:807\u201319.","journal-title":"Nat Genet"},{"key":"6323_CR61","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/thno.73235","volume":"12","author":"R Shi","year":"2022","unstructured":"Shi R, Wang X, Wu Y, Xu B, Zhao T, Trapp C, et al. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics. 2022;12:4181\u201399.","journal-title":"Theranostics"},{"key":"6323_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015;5:704\u201312.","journal-title":"Cancer Discov"},{"key":"6323_CR63","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-20-1888","volume":"27","author":"RG Vile","year":"2021","unstructured":"Vile RG, Melcher A, Pandha H, Harrington KJ, Pulido JS. APOBEC and cancer viroimmunotherapy: thinking the unthinkable. Clin Cancer Res. 2021;27:3280\u201390.","journal-title":"Clin Cancer Res"},{"key":"6323_CR64","unstructured":"Donward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003. https:\/\/www.nature.com\/articles\/nrc969. Accessed 8 Jul 2024."},{"key":"6323_CR65","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","volume":"66","author":"N Chen","year":"2017","unstructured":"Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, et al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother. 2017;66:1175\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"6323_CR66","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 TS, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083-1099.e6.","journal-title":"Immunity"},{"key":"6323_CR67","doi-asserted-by":"publisher","first-page":"175883591988554","DOI":"10.1177\/1758835919885540","volume":"11","author":"M Cinausero","year":"2019","unstructured":"Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, et al. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Ther Adv Med Oncol. 2019;11:1758835919885540.","journal-title":"Ther Adv Med Oncol"},{"key":"6323_CR68","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coi.2017.01.004","volume":"45","author":"F Concha-Benavente","year":"2017","unstructured":"Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol. 2017;45:52.","journal-title":"Curr Opin Immunol"},{"key":"6323_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/0008-5472.CAN-2522-2","volume":"64","author":"F Herrmann","year":"2004","unstructured":"Herrmann F, Lehr H-A, Drexler I, Sutter G, Hengstler J, Wollscheid U, et al. HER-2\/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 2004;64:215\u201320.","journal-title":"Cancer Res"},{"key":"6323_CR70","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood.2023020731","volume":"143","author":"T Brummer","year":"2024","unstructured":"Brummer T, Zeiser R. The role of the MDM2\/p53 axis in antitumor immune responses. Blood. 2024;143:2701\u20139.","journal-title":"Blood"},{"key":"6323_CR71","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/blood.2022016082","volume":"140","author":"JNHG Ho","year":"2022","unstructured":"Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer E-P, Gonzalo N\u00fa\u00f1ez N, et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation. Blood. 2022;140:1167\u201381.","journal-title":"Blood"},{"key":"6323_CR72","doi-asserted-by":"publisher","first-page":"086","DOI":"10.1158\/1535-7163.TARG-19-A086","volume":"18","author":"AW Tolcher","year":"2019","unstructured":"Tolcher AW, Karim R, Tang Y, Ji J, Wang H, Meng L, et al. Abstract A086: phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in US. Mol Cancer Ther. 2019;18:086.","journal-title":"Mol Cancer Ther"},{"key":"6323_CR73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120540119","volume":"119","author":"E Oreskovic","year":"2022","unstructured":"Oreskovic E, Wheeler EC, Mengwasser KE, Fujimura E, Martin TD, Tothova Z, et al. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc Natl Acad Sci. 2022;119: e2120540119.","journal-title":"Proc Natl Acad Sci"},{"key":"6323_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006643","volume":"11","author":"Y Song","year":"2023","unstructured":"Song Y, Peng Y, Qin C, Wang Y, Yang W, Du Y, et al. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J Immunother Cancer. 2023;11: e006643.","journal-title":"J Immunother Cancer"},{"key":"6323_CR75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature23469","volume":"549","author":"V Cardoso","year":"2017","unstructured":"Cardoso V, Chesn\u00e9 J, Ribeiro H, Garc\u00eda-Cassani B, Carvalho T, Bouchery T, et al. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature. 2017;549:277\u201381.","journal-title":"Nature"},{"key":"6323_CR76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coi.2018.11.002","volume":"56","author":"CS Klose","year":"2019","unstructured":"Klose CS, Artis D. Neuronal regulation of innate lymphoid cells. Curr Opin Immunol. 2019;56:94\u20139.","journal-title":"Curr Opin Immunol"},{"key":"6323_CR77","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.it.2020.08.009","volume":"41","author":"I Meininger","year":"2020","unstructured":"Meininger I, Carrasco A, Rao A, Soini T, Kokkinou E, Mj\u00f6sberg J. Tissue-specific features of innate lymphoid cells. Trends Immunol. 2020;41:902\u201317.","journal-title":"Trends Immunol"},{"key":"6323_CR78","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41:573\u201380.","journal-title":"Cancer Cell"},{"key":"6323_CR79","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: state of the field, emerging directions. Cell. 2023;186:1689\u2013707.","journal-title":"Cell"},{"key":"6323_CR80","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/s41418-023-01209-x","volume":"30","author":"B Ducarouge","year":"2023","unstructured":"Ducarouge B, Redavid A-R, Victoor C, Chira R, Fonseca A, Hervieu M, et al. Netrin-1 blockade inhibits tumor associated myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. Cell Death Differ. 2023;30:2201\u201312.","journal-title":"Cell Death Differ"},{"key":"6323_CR81","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.2147\/CMAR.S179680","volume":"10","author":"M Tong","year":"2018","unstructured":"Tong M, Wang J, He W, Wang Y, Pan H, Li D, et al. Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res. 2018;10:4501\u20137.","journal-title":"Cancer Manag Res"},{"key":"6323_CR82","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane J-P, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136.","journal-title":"Nat Commun"},{"key":"6323_CR83","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","volume":"517","author":"H Wang","year":"2021","unstructured":"Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett. 2021;517:96\u2013104.","journal-title":"Cancer Lett"},{"key":"6323_CR84","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1078-0432.CCR-16-1946","volume":"23","author":"C Pereira","year":"2017","unstructured":"Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res. 2017;23:3203\u201313.","journal-title":"Clin Cancer Res"},{"key":"6323_CR85","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature11935","volume":"494","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller M-C, Shaikh N, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494:492\u20136.","journal-title":"Nature"},{"key":"6323_CR86","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11:2983\u201394.","journal-title":"Acta Pharm Sin B"},{"key":"6323_CR87","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41467-018-07927-y","volume":"10","author":"AM Heijink","year":"2019","unstructured":"Heijink AM, Talens F, Jae LT, van Gijn SE, Fehrmann RSN, Brummelkamp TR, et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat Commun. 2019;10:100.","journal-title":"Nat Commun"},{"key":"6323_CR88","doi-asserted-by":"publisher","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109:djw199.","journal-title":"J Natl Cancer Inst"},{"key":"6323_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1087-y","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019. https:\/\/doi.org\/10.1186\/s12943-019-1087-y.","journal-title":"Mol Cancer"},{"key":"6323_CR90","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28:411\u20139.","journal-title":"Int Immunol"},{"key":"6323_CR91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06384-w","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, Wang B, Tu J, Liu C, Wang Y, Chen J, et al. ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I. Cell Death Dis. 2024;15:1\u201314.","journal-title":"Cell Death Dis"},{"key":"6323_CR92","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1038\/s41467-024-52915-0","volume":"15","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al. The genomic and transcriptomic landscape of metastastic urothelial cancer. Nat Commun. 2024;15:8603.","journal-title":"Nat Commun"},{"key":"6323_CR93","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"6323_CR94","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(21)00582-9","volume":"23","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological study. Lancet Oncol. 2022;23:172\u201384.","journal-title":"Lancet Oncol"},{"key":"6323_CR95","doi-asserted-by":"publisher","unstructured":"Langtry A, Rabadan R, Alonso L, Eijck C van, Macarulla T, Lawlor RT, et al. HLA-A*02:01 allele is associated with decreased risk and a longer survival in pancreatic cancer: results from an exhaustive analysis of the HLA variation in PDAC. medRxiv; 2024. p. 2024.08.29.24312704. https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2024.08.29.24312704v1.","DOI":"10.1101\/2024.08.29.24312704v1"},{"key":"6323_CR96","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1101\/gr.248922.119","volume":"29","author":"J Attig","year":"2019","unstructured":"Attig J, Young GR, Hosie L, Perkins D, Encheva-Yokoya V, Stoye JP, et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res. 2019;29:1578\u201390.","journal-title":"Genome Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:20:09Z","timestamp":1743960009000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6323"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06323-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.25.620156","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted with appropriate authorization from the Galician Regional Research Ethics Committee (2019\/046) and from the Ethics Committee from Hospital \u201c12 de Octubre\u201d (17\/094) following the Helsinki Declaration of 1975 and all patients signed informed consent approving their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"404"}}